Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Bomedemstat · MK-3543, IMG-7289

Small molecule · Inhibitor of lysine-specific demethylase 1 (KDM1A) · developed by Merck &

Phase 2/3 Most advanced trial

MRK Developer

1 Registered trials

What is Bomedemstat?

Bomedemstat is an orally available, irreversible inhibitor of lysine-specific demethylase 1 (LSD1). It enhances H3K4 methylation to increase tumor suppressor gene expression and promotes H3K9 methylation to decrease tumor-promoting gene transcription. It is studied in polycythemia vera.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MK-3543, IMG-7289
Drug type: Small molecule
Targets: lysine-specific demethylase 1 (KDM1A)
Mechanism: Inhibitor of lysine-specific demethylase 1 (KDM1A)
Pathways: H3K4 methylation, H3K9 methylation, tumor suppressor gene expression
Therapy area: Oncology
Developer: Merck & Co. (MRK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: Y2T4ALDEAT

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07722611	Phase 2/3	Polycythemia Vera	Recruiting	MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Polycythemia Vera

More from Merck &

BCG Live FDA approved Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Letermovir FDA approved Pembrolizumab FDA approved Probenecid FDA approved Alimatravir Phase 2 Calderasib Phase 3 Favezelimab Phase 1/2

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Bomedemstat

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z